About Evosep
Evosep is a company based in Odense (Denmark) founded in 2016 by Ole Vorm was acquired by Nordic Capital in November 2025. Evosep has raised $48.78 million across 5 funding rounds from investors including Novo Holdings and Nordic Capital. Evosep offers products and services including Evosep One, Evotip, and Columns and Emitters. Evosep operates in a competitive market with competitors including Ovizio, Curiox, Pressure BioSciences, inveox and AcouSort, among others.
- Headquarter Odense, Denmark
- Founders Ole Vorm
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evosep Aps
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$48.78 M (USD)
in 5 rounds
-
Latest Funding Round
$42.57 M (USD), Series A
Jan 09, 2023
-
Investors
Novo Holdings
& 1 more
-
Employee Count
Not available
-
Acquired by
Nordic Capital
(Nov 18, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evosep
Evosep offers a comprehensive portfolio of products and services, including Evosep One, Evotip, and Columns and Emitters.
Platform for standardized, high-speed clinical proteomics analysis.
Tool that speeds up sample loading and reduces carry-over in proteomics.
Components for enhancing liquid chromatography in research applications.
People of Evosep
Unlock access to complete
Funding Insights of Evosep
Evosep has successfully raised a total of $48.78M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $42.57 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evosep
Evosep has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novo Holdings and Nordic Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Evosep
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evosep
Investment portfolio details for Evosep
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evosep
Detailed financials for Evosep
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evosep Comparisons
Peer comparison for Evosep
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evosep
Evosep operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ovizio, Curiox, Pressure BioSciences, inveox and AcouSort, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Imaging systems and AI software for microscopes are developed.
|
|
| Locked | Locked | Locked |
Wall-less plates and washers are developed for automated cell-based assays.
|
|
| Locked | Locked | Locked |
Biomolecular reactions are controlled via pressure cycling technology.
|
|
| Locked | Locked | Locked |
Automated solutions for biopsy sample preparation in laboratories are provided.
|
|
| Locked | Locked | Locked |
Microfluidic acoustofluidics technology for cell separation is developed.
|
Detailed competitors of Evosep
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evosep
Complete news archive for Evosep
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evosep
Evosep was founded in 2016.
Evosep is headquartered in Odense, Denmark.
Evosep is a funded company, having raised a total of $48.78M across 5 funding rounds to date.
Evosep was founded in 2016 in Odense, Denmark, and operates within the clinical proteomics sector. Integrated systems for sample separation and purification are provided through products such as the Evosep One platform and disposable Evotips trap-columns. These enable desalting and cleaning of samples for chromatography analysis. Applications encompass diagnostics, biomarker discovery in humans and plants, and related fields in proteomics research.
Evosep offers Evosep One, Evotip, and Columns and Emitters.
Evosep has 2 investors. Key investors include Novo Holdings, and Nordic Capital.
The valuation of Evosep is $8.84M as of Dec 2018.